Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencySun, 09 Jun 2024 02:20:38 +0200Thu, 21 Mar 2024 11:20:00 +0100Libmyris : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5947_en_2.pdfLibmyris : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5947_en_2.pdfThu, 21 Mar 2024 11:20:00 +0100Human medicineHuman medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 3, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/libmyrisHuman medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 3, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/libmyrisThu, 21 Mar 2024 09:01:00 +0100Human medicine